IDST for BTKi AEs
Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies

Released: January 07, 2025

Expiration: January 06, 2026

About This Tool & Disclaimer

Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies

Clinical Care Options, LLC, is grateful to Toby A Eyre, MBChB, MD; Arnon Kater, MD, PhD; Vincent Ribrag, MD; Stephan Stilgenbauer, MD; and Alessandra Tedeschi, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in November 2024 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on the optimal management of AEs in patients with cancer who are receiving BTK inhibitors.

A series of questions allows you to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include disease type, whether BTK inhibitor therapy has been initiated, which BTK inhibitor is being used, whether an AE is present or an invasive procedure is planned, and the type and severity of the AE if present.

It should be noted that these are not exclusive characteristics when managing AEs in patients with cancer who are receiving BTK inhibitor therapy. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate.

This tool assumes that the patient is an adult diagnosed with CLL/SLL, MCL, MZL, or WM who is considering or has already started BTK inhibitor therapy.

Based on the characteristics entered, the tool will display expert-based recommendations for that specific patient case.

© 2024 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices in monitoring and managing adverse events that can occur in patients with cancer treated with BTK inhibitor therapy with expert guidance from: Toby A Eyre, MBChB, MD; Arnon Kater, MD, PhD; Vincent Ribrag, MD; Stephan Stilgenbauer, MD; and Alessandra Tedeschi, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content